BRPI0516992A8 - Método de potencializar modulação imune e inflamatória para célula e terapia de droga - Google Patents

Método de potencializar modulação imune e inflamatória para célula e terapia de droga

Info

Publication number
BRPI0516992A8
BRPI0516992A8 BRPI0516992A BRPI0516992A BRPI0516992A8 BR PI0516992 A8 BRPI0516992 A8 BR PI0516992A8 BR PI0516992 A BRPI0516992 A BR PI0516992A BR PI0516992 A BRPI0516992 A BR PI0516992A BR PI0516992 A8 BRPI0516992 A8 BR PI0516992A8
Authority
BR
Brazil
Prior art keywords
immune
enhancement
cell
drug therapy
inflammatory
Prior art date
Application number
BRPI0516992A
Other languages
English (en)
Inventor
Willing Alison
R Sanberg Paul
B Newman Mary
Davis Sanberg Cyndy
Original Assignee
Univ South Florida
Saneron Ccel Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ South Florida, Saneron Ccel Therapeutics Inc filed Critical Univ South Florida
Publication of BRPI0516992A publication Critical patent/BRPI0516992A/pt
Publication of BRPI0516992A8 publication Critical patent/BRPI0516992A8/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/51—Umbilical cord; Umbilical cord blood; Umbilical stem cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/12—Pulmonary diseases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/324—Coronary artery diseases, e.g. angina pectoris, myocardial infarction

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Developmental Biology & Embryology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Virology (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Reproductive Health (AREA)
  • Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

MÉTODO DE POTENCIALIZAR MODULAÇÃO IMUNE E INFLAMATÓRIA PARA CÉLULA E TERAPIA DE DROGA Um método para reparar dano a tecido de animal devido a uma reação de inflamação em um animal tendo as etapas de fornecer células sanguíneas de cordão umbilical (UCBCs) em uma forma farmaceuticamente aceitável; e administrar uma dose suficiente de UCBC em um tempo ótimo, desse modo reduzindo a lesão proveniente da reação inflamatória. Também é fornecido um método de tratar acidente cerebrovascular, inflamação aguda do sistema nervoso central, esclerose múltipla, isquemia do miocárdio, e sofrimento broncopulmonar neonatal. Para determinar o tempo ótimo de administração de UCBCs, é fornecido um kit que contém anticorpos para IL-8 e MCP-1.
BRPI0516992A 2004-10-22 2005-10-24 Método de potencializar modulação imune e inflamatória para célula e terapia de droga BRPI0516992A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62134104P 2004-10-22 2004-10-22
PCT/US2005/038565 WO2006047593A2 (en) 2004-10-22 2005-10-24 Method of potentiating inflammatory and immune modulation for cell and drug therapy

Publications (2)

Publication Number Publication Date
BRPI0516992A BRPI0516992A (pt) 2008-09-30
BRPI0516992A8 true BRPI0516992A8 (pt) 2018-04-03

Family

ID=36228421

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0516992A BRPI0516992A8 (pt) 2004-10-22 2005-10-24 Método de potencializar modulação imune e inflamatória para célula e terapia de droga

Country Status (3)

Country Link
US (1) US20060159666A1 (pt)
BR (1) BRPI0516992A8 (pt)
WO (1) WO2006047593A2 (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9694038B2 (en) * 2000-04-06 2017-07-04 Wayne P. Franco Combination growth factor therapy and cell therapy for treatment of acute and chronic diseases of the organs
WO2005059115A1 (en) * 2003-12-15 2005-06-30 University Of South Florida Compositions and methods for enhancing neuroprotection via administration of stem cells and blood brain barrier permeabilizers
US20070178073A1 (en) * 2006-02-01 2007-08-02 Samsung Life Public Welfare Foundation Composition Comprising Separated or Proliferated Cells from Umbilical Cord Blood for Treating Developmental and/or Chronic Lung Disease
WO2010031006A1 (en) * 2008-09-12 2010-03-18 Cryopraxis Criobiologia Ltda. Ischemic tissue cell therapy
US9795652B2 (en) * 2010-02-25 2017-10-24 University Of South Florida Use of endogenous antioxidant proteins in the treatment of stroke
WO2011143415A1 (en) 2010-05-12 2011-11-17 Abt Holding Company Modulation of splenocytes in cell therapy
WO2011143411A1 (en) * 2010-05-12 2011-11-17 Abt Holding Company Modulation of splenocytes in cell therapy for traumatic brain injury
US9078878B2 (en) 2010-12-01 2015-07-14 Alderbio Holdings Llc Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
US9067988B2 (en) 2010-12-01 2015-06-30 Alderbio Holdings Llc Methods of preventing or treating pain using anti-NGF antibodies
US9539324B2 (en) 2010-12-01 2017-01-10 Alderbio Holdings, Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
US9783602B2 (en) 2010-12-01 2017-10-10 Alderbio Holdings Llc Anti-NGF compositions and use thereof
US11214610B2 (en) 2010-12-01 2022-01-04 H. Lundbeck A/S High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
US10765706B2 (en) 2015-09-03 2020-09-08 University Of South Florida Method of stem cell delivery into the brain during chronic disease using blood brain barrier permeabilizers
EP3568020A4 (en) * 2017-01-12 2020-11-11 Duke University COMPOSITIONS AND METHODS FOR THE TREATMENT OF DEMYELINIZING CONDITIONS
US20210275583A1 (en) * 2017-01-12 2021-09-09 Duke University Compositions and methods for the treatment of demyelinating conditions
US11278575B2 (en) 2018-07-12 2022-03-22 Duke University Compositions and methods for the treatment of demyelinating conditions

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5268164A (en) * 1990-04-23 1993-12-07 Alkermes, Inc. Increasing blood-brain barrier permeability with permeabilizer peptides
AU2001251689A1 (en) * 2000-02-10 2001-08-20 The Research Foundation Of State University Of New York A method for detecting bacterial exacerbations of chronic lung disease
AU4346401A (en) * 2000-03-09 2001-09-17 Cryo Cell Int Human cord blood as a source of neural tissue for repair of the brain and spinalcord
US20040157253A1 (en) * 2003-02-07 2004-08-12 Millennium Pharmaceuticals, Inc. Methods and compositions for use of inflammatory proteins in the diagnosis and treatment of metabolic disorders
US20040197310A1 (en) * 2003-02-12 2004-10-07 Sanberg Paul R. Compositions and methods for using umbilical cord progenitor cells in the treatment of myocardial infarction
AU2004212009B2 (en) * 2003-02-13 2010-07-29 Celularity Inc. Use of umbilical cord blood to treat individuals having a disease, disorder or condition

Also Published As

Publication number Publication date
WO2006047593A3 (en) 2009-05-07
WO2006047593A2 (en) 2006-05-04
BRPI0516992A (pt) 2008-09-30
US20060159666A1 (en) 2006-07-20

Similar Documents

Publication Publication Date Title
BRPI0516992A8 (pt) Método de potencializar modulação imune e inflamatória para célula e terapia de droga
Denham Exercise and epigenetic inheritance of disease risk
Chung et al. Clozapine increases both acetylcholine and dopamine release in rat ventral hippocampus: role of 5-HT1A receptor agonism
BR112013004917A2 (pt) terapias de células tronco alogênicas sistêmicas para tratamento de doenças em animais.
AR039985A1 (es) Compuesto de pirimidinona, composicion farmaceutica que lo comprende y su uso para la elaboracion de esta ultima
BR0317898A (pt) Imunoterapia de malignidades de células b e doenças auto-imunes usando anticorpos não conjugados e conjugados, combinações de anticorpos e proteìnas de fusão
BRPI0414455A (pt) métodos para usar células regenerativas no tratamento de doença vascular periférica e distúrbios afins
SG10201903512SA (en) Bile Acid Recycling Inhibitors For Treatment Of Pediatric Cholestatic Liver Diseases
BR112013004685A2 (pt) composição e método para reparação e regeneração muscular
UA124239U (uk) Спосіб лікування раку молочної залози
CO5590913A2 (es) Terapia de combinacion antivirica
BRPI0919020B8 (pt) uso de células de linhagem monocitária enriquecidas para tratar isquemia e para tratar angina pectoris
AR078224A1 (es) Composicon para el tratamiento del cancer de prostata
Zhang et al. Protective effect of electroacupuncture at the Neiguan point in a rabbit model of myocardial ischemia-reperfusion injury
WO2012044783A3 (en) Method of achieving a thymosin beta 4 concentration in a human patient
Wang et al. The beneficial effect of electro-acupuncture given at PC6 (Neiguan-point) by the increase in cardiac transient outward K+ current channel which depends on the gene and protein expressions in artificially induced myocardial ischemia rats
IL141160A0 (en) A pharmaceutical composition containing a precursor of uric acid
ES2655834T3 (es) Composición farmacéutica para inhibir la autofagia de las neuronas motoras y uso de la misma
Pandey et al. Striatal dopamine level contributes to hydroxyl radical generation and subsequent neurodegeneration in the striatum in 3-nitropropionic acid-induced Huntington's disease in rats
IL182462A0 (en) Treatment of graft-versus-host disease and leukemia with beclomethasone dipropionate and prednisone
BR112013016554A2 (pt) métodos e composições úteis para promover sono nos animais
CO6190520A2 (es) Metodos para el tratamiento del abuso adiccion y dependencia del alcohol
RU2004128907A (ru) Способ лечения больных хроническим простатитом
CN117137911A (zh) 一种nampt的激活剂及应用
Rosko et al. 4492 The role of creatine in developmental myelination and remyelination

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]
B15K Others concerning applications: alteration of classification

Ipc: C12N 5/00 (2006.01), A61K 35/51 (2015.01), A61P 29

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL